Mode
Text Size
Log in / Sign up
N/A N=117 Treatment

Prospective Study of Lens Performance of a Monthly Replacement Lens at Two Weeks and Four Weeks

Myopia · Astigmatism · Presbyopia

Enrolled (actual)
117
Serious AEs
0.0%
Results posted
Jun 2012
Primary outcome: Primary: Overall Comfort — 8.6 Units on a scale

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
lotrafilcon B contact lens (Device)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
CIBA VISION
Primary completion
Apr 2011

Outcome Measures

OutcomeResultp-value
PRIMARY
Overall Comfort
8.1
PRIMARY
Overall Comfort
8.1
PRIMARY
End of Day Dryness
7.0
PRIMARY
End of Day Dryness
7.0
PRIMARY
Ocular Redness
9.0
PRIMARY
Ocular Redness
9.0
PRIMARY
Visual Clarity
8.2
PRIMARY
Visual Clarity
8.2
PRIMARY
Lens Deposits
0.8
PRIMARY
Lens Deposits
0.8
PRIMARY
Corrected Visual Acuity
0.04
PRIMARY
Corrected Visual Acuity
0.04

Summary

The purpose of this study is to compare the overall performance of a monthly replacement contact lens when worn for one month and when worn for two weeks.

Eligibility Criteria

Inclusion Criteria

  • Habitual and successful wearers of contact lenses made of lotrafilcon B material for at least 4 weeks prior to enrollment.
  • Good general health.
  • Sphere requirement in the range +6.00 to -10.00 with astigmatism or multifocal correction or no astigmatism or multifocal correction.
  • Ability to comply with all protocol-mandated procedures and to attend all scheduled office visits.
  • Other protocol-defined inclusion criteria may apply.

Exclusion Criteria

  • Anterior segment abnormalities (i.e., cataracts, opacities, etc.) or active anterior segment disease.
  • Administration of any investigational drug or device within 14 days of study initiation.
  • Use of any eye drops with a pharmacological effect within 7 days of Visit 1.
  • Known local or systemic hypersensitivity to contact lens cleaning and disinfecting solutions.
  • Post-refractive surgery.
  • Currently pregnant or lactating by case history.
  • Other protocol-defined exclusion criteria may apply.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01293240). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search